中国研究发现新型 CAR-T 疗法可能是安全、低成本的选择 || Chinese study finds new CAR-T therapy may be safe, low-cost option
AI Summary:
---------------
这种治疗是高度专业化和个性化的,这也是它如此昂贵的原因。它需要提取患者的 T 细胞,对其进行基因改造,然后将其送回患者体内。
上海的一个研究小组开发的新版本工作原理略有不同。它被称为TyU19,使用健康捐献者的T细胞,然后对其进行基因改造。研究小组说,这是一种通用药物,因此一批药物可以用于治疗许多病人,从而大大降低了成本。
它是由生物技术公司BRL Medicine、华东师范大学和上海长征医院的科学家开发的。他们的研究成果于本周二发表在同行评审期刊《细胞》上。
根据 BRL Medicine 的声明,TyU19 的 "最突出优势 "是可以大规模生产,同时方便、安全、成本低、疗效好。
它表示,这种疗法还可以克服现有个性化 CAR-T 疗法的 "痛点",包括准备周期长、失败风险高和成本极高。
在这项研究中,细胞疗法被用于治疗三名自身免疫性疾病患者--一名难治性免疫介导坏死性肌病(IMNM)患者和两名弥漫性皮肤系统性硬化症(SSc)患者。科学家们说,这是首次使用通用 CAR-T 疗法成功治疗自身免疫性疾病。
据说,在接受治疗 6 个月后的随访中,这三名患者的病情都得到了 "深度缓解",没有发现严重的不良反应。
IMNM和SSc都是风湿免疫性疾病--一类影响全球8%以上人口的疾病。IMNM是一种罕见的严重疾病,以肌肉纤维坏死和进行性肌无力为特征,而SSc则以广泛的器官纤维化为特征。
中国著名病毒学家和免疫学家 George Gao Fu 说,这种新疗法很有希望。
本周二,在中国社交媒体 "生物艺术"(BioArt)上发表的一篇文章中,高志强指出,这项研究的样本量很小。他说,这些都是高风险和难治疗的病例,但其中一些人的纤维化已经得到了逆转。
"中国疾病预防控制中心原主任高志强说:"这些结果显示了这种疗法的潜力,值得今后在更大规模的临床试验中进一步验证。
---------------
The treatment is highly specialised and personalised, which is why it remains so expensive. It involves extracting a patient’s T-cells, genetically modifying them and then returning them to the patient’s body.
The new version developed by a team of researchers in Shanghai works a little differently. Called TyU19, it uses T-cells from healthy donors then genetically modifies them. The team said it was a universal medicine, so a batch could be used to treat many patients, greatly reducing the cost.
It was developed by scientists from biotech company BRL Medicine, East China Normal University and Shanghai Changzheng Hospital. The results of their study were published in peer-reviewed journal Cell on Tuesday.
According to a statement from BRL Medicine, the “most outstanding advantage” of TyU19 is that it can be manufactured on a large scale, while being convenient, safe, low-cost and with good efficacy.
It said the treatment could also overcome the “pain points” of existing, personalised CAR-T therapies, including a long preparation cycle, high risk of failure and extremely high cost.
For the study, the cell therapy was used to treat three patients with autoimmune diseases – one with refractory immune-mediated necrotising myopathy (IMNM) and two patients with diffuse cutaneous systemic sclerosis (SSc). The scientists said it was the first time autoimmune diseases had been successfully treated using a general purpose CAR-T therapy.
During a follow-up six months after they were treated, all three patients were said to be in “deep remission” with no serious adverse events observed.
IMNM and SSc are both rheumatic immune diseases – a group of diseases that affects more than 8 per cent of the world’s population. IMNM is a rare and severe disease characterised by muscle fibre necrosis and progressive muscle weakness, while SSc is characterised by extensive organ fibrosis.
George Gao Fu, a leading Chinese virologist and immunologist, said the new treatment was promising.
In a post on Chinese social media account “BioArt” on Tuesday, Gao noted that the sample size of the study was small. He said they were high-risk and difficult-to-treat cases but the fibrosis had been reversed for some of them.
“These results show the potential of this therapy, which deserves to be further validated in larger clinical trials in the future,” said Gao, former head of the Chinese Centre for Disease Control and Prevention.
via News - South China Morning Post (author: Dannie Peng)
AI Summary:
---------------
这种治疗是高度专业化和个性化的,这也是它如此昂贵的原因。它需要提取患者的 T 细胞,对其进行基因改造,然后将其送回患者体内。
上海的一个研究小组开发的新版本工作原理略有不同。它被称为TyU19,使用健康捐献者的T细胞,然后对其进行基因改造。研究小组说,这是一种通用药物,因此一批药物可以用于治疗许多病人,从而大大降低了成本。
它是由生物技术公司BRL Medicine、华东师范大学和上海长征医院的科学家开发的。他们的研究成果于本周二发表在同行评审期刊《细胞》上。
根据 BRL Medicine 的声明,TyU19 的 "最突出优势 "是可以大规模生产,同时方便、安全、成本低、疗效好。
它表示,这种疗法还可以克服现有个性化 CAR-T 疗法的 "痛点",包括准备周期长、失败风险高和成本极高。
在这项研究中,细胞疗法被用于治疗三名自身免疫性疾病患者--一名难治性免疫介导坏死性肌病(IMNM)患者和两名弥漫性皮肤系统性硬化症(SSc)患者。科学家们说,这是首次使用通用 CAR-T 疗法成功治疗自身免疫性疾病。
据说,在接受治疗 6 个月后的随访中,这三名患者的病情都得到了 "深度缓解",没有发现严重的不良反应。
IMNM和SSc都是风湿免疫性疾病--一类影响全球8%以上人口的疾病。IMNM是一种罕见的严重疾病,以肌肉纤维坏死和进行性肌无力为特征,而SSc则以广泛的器官纤维化为特征。
中国著名病毒学家和免疫学家 George Gao Fu 说,这种新疗法很有希望。
本周二,在中国社交媒体 "生物艺术"(BioArt)上发表的一篇文章中,高志强指出,这项研究的样本量很小。他说,这些都是高风险和难治疗的病例,但其中一些人的纤维化已经得到了逆转。
"中国疾病预防控制中心原主任高志强说:"这些结果显示了这种疗法的潜力,值得今后在更大规模的临床试验中进一步验证。
---------------
The treatment is highly specialised and personalised, which is why it remains so expensive. It involves extracting a patient’s T-cells, genetically modifying them and then returning them to the patient’s body.
The new version developed by a team of researchers in Shanghai works a little differently. Called TyU19, it uses T-cells from healthy donors then genetically modifies them. The team said it was a universal medicine, so a batch could be used to treat many patients, greatly reducing the cost.
It was developed by scientists from biotech company BRL Medicine, East China Normal University and Shanghai Changzheng Hospital. The results of their study were published in peer-reviewed journal Cell on Tuesday.
According to a statement from BRL Medicine, the “most outstanding advantage” of TyU19 is that it can be manufactured on a large scale, while being convenient, safe, low-cost and with good efficacy.
It said the treatment could also overcome the “pain points” of existing, personalised CAR-T therapies, including a long preparation cycle, high risk of failure and extremely high cost.
For the study, the cell therapy was used to treat three patients with autoimmune diseases – one with refractory immune-mediated necrotising myopathy (IMNM) and two patients with diffuse cutaneous systemic sclerosis (SSc). The scientists said it was the first time autoimmune diseases had been successfully treated using a general purpose CAR-T therapy.
During a follow-up six months after they were treated, all three patients were said to be in “deep remission” with no serious adverse events observed.
IMNM and SSc are both rheumatic immune diseases – a group of diseases that affects more than 8 per cent of the world’s population. IMNM is a rare and severe disease characterised by muscle fibre necrosis and progressive muscle weakness, while SSc is characterised by extensive organ fibrosis.
George Gao Fu, a leading Chinese virologist and immunologist, said the new treatment was promising.
In a post on Chinese social media account “BioArt” on Tuesday, Gao noted that the sample size of the study was small. He said they were high-risk and difficult-to-treat cases but the fibrosis had been reversed for some of them.
“These results show the potential of this therapy, which deserves to be further validated in larger clinical trials in the future,” said Gao, former head of the Chinese Centre for Disease Control and Prevention.
via News - South China Morning Post (author: Dannie Peng)